Merdury Biopharmaceutical Corporation (TPEX:6932)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Pharmaceuticals	4.96M	1.03M	2.68M	-
Pharmaceuticals Growth	380.45%	-61.46%	-	-
Total	4.96M	1.03M	2.68M	-
Total Growth	380.45%	-61.46%	-	-

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Taiwan	4.96M	-	1.45M	-
United State	-	-	1.23M	-
Total	4.96M	-	2.68M	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 18, 2026

Data Sources Report a data error